Adding hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery significantly improved overall survival (OS) in women with platinum-sensitive, recurrent epithelial ovarian carcinoma, ...

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial This was a multicenter randomized phase ...

HIPEC addition to SCS did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer patients. Both SCS alone and SCS with HIPEC groups exhibited similar safety profiles, ...

FOX CHASE (WPVI) -- HIPEC is an often overlooked form of chemotherapy, with a long track record. It's improving survival rates in some abdominal cancers, however, some patients and doctors may not ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with surgery plus intraperitoneal chemotherapy, according to a randomized trial.

Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

Please provide your email address to receive an email when new articles are posted on . In this video, Robert DeBernardo, MD, discusses his research on hyperthermic intraperitoneal chemotherapy among ...

CHICAGO — Intraperitoneal (IP) chemotherapy is now an alternative to intravenous (IV) administration that "must be discussed" for women with cytoreduced ovarian cancer, several experts said here at ...

VIRGINIA BEACH, Va. (WAVY) — Just when Becky Kirby found love, she got the diagnosis. Kirby and her husband were returning from a one-year anniversary trip when she felt the pain in her abdomen that ...